AVISTONE PHARMACEUTICALS
Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.
AVISTONE PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Oncology
Founded:
2011-01-01
Address:
Beijing, Beijing, China
Country:
China
Website Url:
http://www.en.avistonebio.com
Total Employee:
251+
Status:
Active
Contact:
010- 84148921
Email Addresses:
[email protected]
Total Funding:
340.69 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Mobile Non Scaleable Content Pound Sterling Japanese Yen
Similar Organizations
Abogen Biosciences
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Integral Molecular
Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Oncora Medical
Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-12-10 | Pearl Biotech | Pearl Biotech acquired by Avistone Pharmaceuticals | N/A |
Investors List
Bain Capital
Bain Capital investment in Series B - Avistone Pharmaceuticals
SDIC Fund Management
SDIC Fund Management investment in Series B - Avistone Pharmaceuticals
IDG Capital
IDG Capital investment in Series B - Avistone Pharmaceuticals
Yanchuang Capital
Yanchuang Capital investment in Series B - Avistone Pharmaceuticals
Cathay Capital
Cathay Capital investment in Series B - Avistone Pharmaceuticals
Bain Capital
Bain Capital investment in Series A - Avistone Pharmaceuticals
Vivo Capital
Vivo Capital investment in Series A - Avistone Pharmaceuticals
Primavera Capital Group
Primavera Capital Group investment in Series A - Avistone Pharmaceuticals
Official Site Inspections
http://www.en.avistonebio.com
- Host name: server-3-167-88-25.iad55.r.cloudfront.net
- IP address: 3.167.88.25
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Avistone Pharmaceuticals"
Avistone Pharmaceuticals - Crunchbase Company …
Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.See details»
Avistone Biotechnology Co., Inc | LinkedIn
Avistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Avistone has an extensive pipeline of targeted therapies ...See details»
Avistone Pharmaceuticals | Bain Capital Life Sciences
Avistone Pharmaceuticals is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Avistone has an extensive portfolio and …See details»
北京鞍石生物科技股份有限公司
北京鞍石生物科技股份有限公司_鞍石生物科技致力于健康服务产业，以为患者提供高质量医药产品作为宗旨。公司药物研发主要涉及肿瘤治疗领域，利用团队在化学和基于结构的药物设计方 …See details»
Avistone Biotechnology - VentureRadar
"Avistone is a clinical-stage biotechnology company based in Beijing, China, focusing on researching and developing innovative therapies for patients with significant unmet medical …See details»
Avistone Pharmaceuticals - Executive Bio, Top Executies, and ...
View the organization profile of Avistone Pharmaceuticals,Ph.D., Peking Union Medical College Before founding Beijing Avistone Biotechnology Co., Ltd., Dr. Shi led Yangzijiang …See details»
Core Team-Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
Master of Science degree in Healthcare, Northumbria University, Newcastle, United Kingdom Responsible for managing Avistone’s overseas clinical operations team. Prior to Avistone, she …See details»
Avistone Biotechnology Co., Inc Overview - SignalHire
Avistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Avistone has an extensive pipeline of targeted …See details»
Chinese Cancer Biotech Avistone Raises $200 Million in …
Dec 9, 2021 (Bloomberg) — Chinese biotechnology company Avistone Pharmaceuticals raised more than $200 million in a series A funding round led by Vivo Capital in one of the largest such deals for the sector. The investment will …See details»
Avistone Pharmaceuticals - Growth Outlook - Crunchbase
Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.See details»
核心团队-北京鞍石生物科技股份有限公司 - avistonebio.com
北京协和医学院博士 •创办鞍石生物前，曾带领扬子江海燕扭亏为盈，领导苏黄止咳胶囊的卓越上市和商业落地，打造国内年销售超二十亿元的重磅产品。 •带领北京浦润奥（现为北京鞍石全 …See details»
www.fatf-gafi.org
Paris, 20 June 2025 – A new FATF report, Complex Proliferation Financing and Sanctions Evasion Schemes, published today, reveals that significant vulnerabilities remain across tSee details»
Investor Relations-Beijing Avistone Pharmaceuticals Biotechnology …
American branch: 850 New Burton Road, Suite 201, City of Dover,County of Kent, State of Delaware Phone: 010- 84148921 Email: [email protected]See details»
Science and innovation-Beijing Avistone Pharmaceuticals …
Beijing Avistone Biotechnology Co.,Ltd. is actively seeking outstanding products and excellent partners worldwide. Partners with the following cooperation opportunities are welcome to …See details»
About us-Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
Inception of Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.; launch of Vebreltinib GBM Phases II/III critical registration for clinical trials; patent approved for Vebreltinib precision …See details»
研发者说 | 愈获新生--讲述他们的故事 - avistonebio.com
Jan 13, 2023 “和临床医生、患者一起，通过创新、真正解决患者未被满足的临床需求，一直是鞍石生物科技发展的核心理念。” 引言： 刚刚过去的9月24日，鞍石生物科技的MET靶点抑制 …See details»
核心团队-北京鞍石生物科技股份有限公司 - avistonebio.com
北京协和医学院博士 创办鞍石生物前，曾带领扬子江海燕扭亏为盈，领导苏黄止咳胶囊的卓越上市和商业落地，打造国内年销售超二十亿元的重磅产品。带领北京浦润奥（现为北京鞍石全资子 …See details»
News and Announcements-Beijing Avistone Pharmaceuticals …
Aug 15, 2024 In the newly released National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2024), …See details»
Company News-Beijing Avistone Pharmaceuticals Biotechnology …
On December 25, 2024, Avistone announced that its wholly-owned subsidiary, Pearl Biotechnology, submitted a New Drug Application (NDA) to Center for Drug Evaluation (CDE) …See details»
关于鞍石_北京鞍石生物科技股份有限公司 - avistonebio.com
9月15日下午，2022中关村国际前沿科技创新大赛生物医药领域决赛在昌平区中关村生命科学园举办，10家硬科技企业从决赛中脱颖而出，成功入围前沿大赛生物医药领域TOP10。See details»